Technology ID
TAB-5037
Immunotherapy for Treating HER2-Positive Breast Cancer
E-Numbers
E-248-2017-0
Lead Inventor
Shevach, Ethan (National Institute of Allergy and Infectious Diseases (NIAID/NIH))
Co-Inventors
DeVico, Angela (National Institute of Allergy and Infectious Diseases (NIAID/NIH))
This technology includes a novel immunotherapy approach designed to target HER2-positive breast cancer cells. It leverages a specific mechanism to enhance the immune system's ability to identify and destroy these cancer cells. The technology demonstrated significant potential in pre-clinical in vivo studies, suggesting it could improve treatment outcomes for patients with HER2-positive breast cancer
Commercial Applications
This technology could be applied in developing new treatment protocols for HER2-positive breast cancer, particularly for patients who have not responded well to existing therapies. It also holds potential as a combination therapy, enhancing the effectiveness of current treatment regimens.
Competitive Advantages
This immunotherapy offers a targeted approach that specifically addresses HER2-positive cancer cells, potentially reducing side effects compared to conventional treatments. Additionally, its mechanism enhances the immune response, which may lead to better efficacy in eliminating cancer cells.
Licensing Contact: